The Efficacy and Safety of Mainstream Medications for Patients With cDMARD-Naïve Rheumatoid Arthritis: A Network Meta-Analysis

• Ngā kaituhi matua: Weiyan Cai (Author), Youyi Gu (Author), Huanqin Cui (Author), Yinyin Cao (Author), Xiaoliang Wang (Author), Yi Yao (Author), Mingyu Wang (Author)
• Hōputu: Pukapuka
• I whakaputaina: Frontiers Media S.A., 2018-03-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Background: The mainstream medications for rheumatoid arthritis (RA) include conventional disease-modifying antirheumatic drugs (cDMARDs), which mostly are methotrexate (MTX), and biologic agents such as adalimumab (ADA), certolizumab (CZP), etanercept (ETN), golimumab (GOL), infliximab (IFX), and t...